This article is more than 5 years old. Information may no longer be current.
Once-daily prostaglandin analog reduces IOP up to 24 hours
Click Here to Manage Email Alerts
IOP was reduced up to 24 hours in patients with open-angle glaucoma or hypertension when treated with a once-daily travoprost ophthalmic solution, according to a study.
“The sustained 30% reduction in IOP seen with travoprost therapy may be a reasonable target for patients with open-angle glaucoma or hypertension,” Harvey DuBiner, MD, and colleagues reported in a poster presented at the World Glaucoma Congress. An IOP reduction threshold for glaucoma patients has yet to be determined.
Seven clinical trials were examined, including a total of 1,563 patients treated with travoprost ophthalmic solution 0.004% monotherapy daily for 12 weeks. IOP was measured at three times during the day (8 a.m. or 9 a.m., 10 a.m. or 11 a.m., and 4 p.m.) at baseline, 2 weeks and 12 weeks.
Average reduction of IOP was7.96mm Hg at week 2 and 8mm Hg at week 12. There was a 30% decrease in IOP for up to 24 hours after treatment.
Travoprost’s IOP-lowering effects peaked as early as 2 weeks after dosing and were maintained throughout the 12 weeks of treatment, the authors said.
Disclosure: DuBiner is on the speaker’s bureau for Alcon.